Dr. Loh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4800 Sand Point Way NE
MB.8.501
Seattle, WA 98105Phone+1 206-987-2106
Summary
- I am a board certified pediatric hematologist-oncologist who specializes in the treatment of children, adolescents, and young adults with high risk leukemia. I am interested in harnessing genomics to add to the accurate diagnosis of leukemia and to utilize this knowledge for optimizing risk stratification and therapeutics.
Education & Training
- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1994
- University of California (San Francisco)Internship, Pediatrics, 1991 - 1992
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1991
Certifications & Licensure
- CA State Medical License 1999 - 2027
- WA State Medical License 2021 - 2026
- MA State Medical License 1994 - 2001
- NC State Medical License 1995 - 1998
- NY State Medical License 1994 - 1996
- CT State Medical License 1994 - 1995
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- Reply to: Accurate Determinants of Outcome in ALL.Ti-Cheng Chang, Wenan Chen, Chunxu Qu, Zhongshan Cheng, Abdelrahman Elsayed
Journal of Clinical Oncology. 2025-03-10 - 2 citationsBlinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.Sumit Gupta, Rachel E Rau, John A Kairalla, Karen R Rabin, Cindy Wang
The New England Journal of Medicine. 2025-02-27 - Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.Yuxuan Liu, Haowen Jiang, Jingjing Liu, Lucille Stuani, Milton Merchant
Biorxiv. 2025-01-30
Press Mentions
- Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-cell ALL of Average or High Risk of RelapseJanuary 13th, 2025
- Seattle Children’s Researchers Greatly Improve Survival for Children Diagnosed with the Most Common Form of Childhood Cancer, Changing the Standard of CareDecember 7th, 2024
- Scientists Identify Genes Linked to Relapse in the Most Common Form of Childhood LeukemiaAugust 12th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: